Through the Boston Pharma deal, GSK aims to strengthen its pipeline, as some of its key products are nearing the end of their exclusivity period.

Penmenvy, GSK’s pentavalent MenABCWY meningococcal vaccine and Blujepa/gepotidacin for treating, uncomplicated urinary tract infection were approved in the United States in the first quarter of ...

This year, GSK expects to launch five new products or line extensions. The FDA has already approved two products — Blujepa (for uncomplicated urinary tract infection) and Penmenvy (the 5-in-1 ...

"The approval of Blujepa is a crucial milestone with uUTIs among the most common infections in women," said GSK's chief scientific offer Tony Wood, pointing out that around 16 million women in the ...

Teos and GSK were the last to report a new setback in TIGIT targeting for non-small cell lung cancer patients. Read why I am ...

Markets have slowly clawed back the losses seen since Donald Trump announced sweeping tariffs at the start of April.

Charlie Carman consults the world's leading artificial intelligence chatbot to find out which UK income stocks it would buy ...

The FTSE 100 is looking a bit livelier after Thursday’s rally, posting modest gains early Friday. The blue chips snapped a two-day losing streak yesterday, however, it does look we are now in a phase ...

Nvidia has been topping up its stake in new IPO firm CoreWeave (NASDAQ:CRWV). Should I buy this AI growth stock that's ...